1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsProvides early-stage funding for highly innovative R&D projects, with active funding areas including blockchain for federal applications and decentralized identity.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: US-based small businesses. Confirm the full requirements in the official notice before applying.
The current listing shows up to $295,000 (Phase I); Up to $2,000,000 (Phase II); Unlimited (Phase III). Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was September 13, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
SBIR Phase I — US Small Business Innovation (Blockchain for Federal Applications) is funded by US Federal Government (across 11 agencies including NIH, DOE, NSF, DoD, DARPA). Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
Small Business Transition Grant for New Entrepreneurs (SBIR) — R43 Phase I is a grant from the National Institutes of Health (NIH) that funds early-stage scientific innovation by small businesses aiming to bring biomedical breakthroughs to the commercial marketplace. The Phase I award supports feasibility research, evaluating technical merit and commercial potential of proposed innovations. Eligible applicants are U.S. small business concerns, particularly new entrepreneurs, applying under PAR-24-131. Awards cover up to approximately $306,872 in total costs for Phase I. The most recent deadline is September 5, 2026.
NIH SBIR/STTR Parent SBIR (R43/R44) Clinical Trial Not Allowed (PA-24-245) is sponsored by National Institutes of Health (NIH). The NIH SBIR program supports small businesses developing innovative technologies that address health-related challenges through Phase I and Phase II funding, focusing on establishing technical feasibility, research and development, and advancing toward commercialization.
Serial SBIR winners build cross-agency portfolios by adapting core technology to DOD, NIH, and NSF missions. Here is how they do it under the 2026 rules.
Read articleThe FY2026 spending package preserves NIH, NSF, and DOE funding while blocking the 15% indirect cost cap. A detailed breakdown of what passed, what is next in the Senate, and how researchers should position themselves.
Read articleOPM's March 2026 rule strips civil service protections from positions deemed policy-influencing — including potentially thousands of grant reviewers and program officers across NSF, NIH, and the Department of Defense. Here's how grant seekers should adapt.
Read article